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humans are Schistosoma hemat-obium (endemic in Africa and the eastern Mediterranean), Schistosomamansoni (endemic in Africa, the Middle East, the Caribbean and South America) and Schistosomajaponicum (endemic mainly in China, Japan and the Philippines) [2] .
According to the largest survey conducted in Egypt, the prevalence of S. hematobium and S. mansoni infections is about 7.8 % and 36.4 % in Upper Egypt and Lower Egypt respectively [3] . S. hematobium, This subsequently leads to portal hypertension (PHT) and hepaticencephalopathy with their sequelae [2] .
Despite availability and efficacy of praziquantel therapy, liver fibrosis, which is the most serious sequelae of chronic schistosomiasis develops in up to 20% of infected individuals [4] . The prognosis and management of advanced hepatic schistosomasis depends largely on the degree of liver fibrosis [5] . Despite being the gold standard in assessing hepatic fibrosis, use of liver biopsy (LB) is limited by poor patients' compliance, its associated morbidity, sampling error, poor intra-and inter-observer concordance, and by being unsuitable for dynamic surveillance [6, 7] . [7, 12] . The performance of TE in staging hepatic fibrosis was tested in a subgroup of Egyptian patients with positive schistosomiasis serology, but they were all coninfected with hepatitis C virus (HCV) [13] . However, it is well known that concurrent HCV and schistosomiasis infections result in an advanced and more severe liver disease than that observed with either disease alone [14] . To our knowledge, no previous study has used TE (FibroScan)as a non-invasive tool in the assessment of hepatic fibrosis in patients with pure chronic schistose-miasis, which is the aim of the present study.
Patients and Methods

Patients
A total of 30 Egyptian patients with mean ± SD age of 42.1 ± 8. <1/160 and all have already received praziquantil therapy for schistosomiasis.
Exclusion criteria
Patients with any of the following conditions or characteristics were excluded from participation: Age <18 or >60 years; active alcohol consumption; pre-existing psychiatric condition, pregnant or breast feeding women; significant clinical comorbidities; patients with co-existent liver disease, e.g. chronic hepatitis C, chronic hepatitis B, or autoimmune liver diseases; patients who were currently on anti-viral therapy or who had completed anti-viral therapy and those who had ascites or focal lesions by abdominal US.
Approval and consent
This study was performed in the Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, Dakahliya, Egypt between December 2013 and December 2014. The study was approved by the local Ethics Committee and the institution's review board, conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines, and each participant gave an informed written consent before being enrolled in the study and before performing the upper endoscopy.
Clinical and laboratory evaluation
The patients were subjected to thorough history taking, clinical examination, routine pre-treatment laboratory work-up including complete blood count, international normalized ratio (INR), and serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, bilirubin, ferritin, and ceruloplasmin. Common terminology criteria Version 4.0 was used to grade the abnormal lab values [15] . Serum samples from all patients were also tested for serological tests including anti-HCV antibodies, HBsAg; HBcAb; anti-nuclear antibody (ANA); anti-smooth muscle antibody (anti-SMA), anti-liver kidney microsomal antibody (anti-LKM), and pregnancy test for female subjects of child bearing potential. Antischistosomal antibodies were tested by the indirect hemagglutination (IHA) test. Previous exposure to Schistosoma was identified by a history of previous contact with canal water and/or receiving antibilharzial therapy with a positive serology titer ≥1/160.
Abdominal US and endoscopy
Abdominal US was performed for all subjects using a Toshiba real time scanning device "AplioM" with a convex probe" to detect the presence of liver fibrosis and signs of portal hypertension (i.e., dilated portal vein >14 mm, dilated splenic vein >9 mm, presence of splenic hilar collaterals and splenomegaly >13 cm). Also, an upper gastrointestinal endoscopy was performed to all patients to assess for signs of PHT and the presence of EV as sequels of SHF.
2.6.
FibroScan TE (FibroScan) was done to determine liver stiffness using the ultrasound TE fibroscan device (Echosens, Paris, France), which consists of a 5-MHz ultrasound transducer probe mounted on the axis of a vibrator. Liver stiffness was measured on the same day as LB. TE measures liver stiffness in a volume that approximates a cylinder 1 cm wide and 4 cm long, between 25 and 65 mm below the skin surface, and the technique was performed according to that described in previous studies [16] . A cutoff value of ≥10.1 Kpa indicates advanced fibrosis (F3-F4).The classification used for grading liver stiffness by TE (FibroScan) was a modification from that described by Castera et al. [17] . F0-F1: 6-7 kPa, F2: 7.1-9.4 kPa, F3: 9.5-12.4 kPa and F4: >12.5 kPa.
Statistical analysis
Data were collected in a pre-formed data collection form prior to entery in a Microsoft Excel Sheet and then were transferred to SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows for analysis. The quantitative data were described with mean and standard deviation (SD) and compared by the Student's t-test.
Qualitative variables were described by number and percent. They were compared by the chi-squared or Fischer's exact test, when appropriate. In all tests, a p value <0.05 was considered significant.
Results
A total of 30 patients were included in this study. Their mean ± SD age and body mass index (BMI) of all patients were 42.1 ± 8. 
Data expressed an n (%).* using a cutoff value of ≥10.1 Kpa indicates advanced fibrosis (F3-F4).
As shown in tab. (3), the sensitivity, specificity, PPV, NPV and accuracy of fibroScan in detecting advanced fibrosis evidenced by presence of spenomegaly were 29.6 %, 100 %, 100 %, 13.64, and 36.7 %.
Similarly, the corresponding performance characteristics of FibroScan in detecting advanced fibrosis evidenced by presence of varices are 28.0 %, 80.0 %, 87.5 %, 18.2 %, and 37.9 % respectively. Descriptive analysis was performed for the laboratory parameters AST, ALT and Bilirubin. Abnormal results for AST and ALT were compared with the Endoscopy, US and FibroScan findings. It was interesting to see only one patient had Grade II ALT results (clinically significant) whereas 7 patients had Grade I AST and ALT results. Grade I abnormality for bilirubin was also noted for 7 patients. There appears no specific pattern for abnormal laboratory results on FibroScan findings because out of these patients only one subject had F4 fibrosis stage, and the subject who had Grade II ALT results has F1 Fibrosis stage as summarized in tab. (4). 
Data expresses as % and (confidence interval).
Conclusion
In conclusion, the present study shows 
